OMXCOP:NOVO_B

Track all markets on TradingView - Graphs are not on time

Hims & Hers stock surges as Novo Nordisk says it will distribute weight-loss drugs on platform

Hims stock surged more than 40% Monday morning on news that Novo Nordisk will distribute its weight-loss drugs through the Hims platform.

(finance.yahoo.com)
💬 🔗
Author
WS Investor 03-09-26
Lilly’s Zepbound Outperforms Wegovy in Obesity Trial, Published in NEJM

Eli Lilly's Zepbound (tirzepatide) delivered significantly greater weight loss than Novo Nordisk’s Wegovy (semaglutide) in the head-to-head SURMOUNT-5 trial, according to results published May 11 in *The New England Journal of Medicine*. Over 72 weeks, Zepbound users lost an average of 20.2% of their body weight versus 13.7% with Wegovy. Zepbound also outperformed on all secondary endpoints, including percentage achieving major weight-loss thresholds and waist circumference reduction. The results, presented at the European Congress on Obesity, further position Zepbound as a leading obesity treatment.
💬 🔗
Author
Global Finance News 05-12-25
Video Thumbnail
03-26-25WS News
Video Thumbnail
03-18-25European Investor